A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 595 in Subjects With Recurrent Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2016
At a glance
- Drugs AMG 595 (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Amgen
- 14 Apr 2016 Status changed from active, no longer recruiting to completed.
- 14 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 14 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.